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In the field of cancer biology, numerous genes or proteins form extremely complex regulatory network, which determines cancer
cell fate and cancer cell survival. p53 is a major tumor suppressor that is lost in more than 50% of human cancers. It has been well
known that a variety of proteins regulate its protein stability, which is essential for its tumor suppressive function. It remains elusive
how we could understand and target p53 stabilization process through network analysis. In this paper we discuss the use of random
walk and stationary distribution to measure the compound effect of a network of genes or proteins. This method is applied to the
network of nine proteins that influence the protein stability of p53 via regulating the interaction between p53 and its regulator
MDM2. Our study identifies that some proteins such as HDAC1 in the network of p53 regulators may have more profound effects
on p53 stability, agreeing with the established findings on HDAC1.This work shows the importance of using mathematical analysis
to dissect the complexity of biology networks in cancer.
1. Introduction
The tumor suppressor p53 is the master transcriptional reg-
ulator whose expression prevents the development of cancer
[1]. Functional p53 expression is lost in about 50% of human
cancer cases [2]. The MDM2 gene, a cellular protooncogene
that is amplified in more than 7% of all human cancer cases
[3], interacts with p53 and counteracts the tumor-suppressive
function of p53 protein through variousmechanisms, includ-
ing blocking its transcriptional activity, exporting it into the
cytoplasm and most importantly promoting its degradation
[4].
MDM2 activities include those of a ubiquitin ligase,
making it capable of targeting uniquitination of p53, which
leads to p53 degradation [5, 6]. The ability of MDM2 to
associate with and target p53 degradation depends highly on
proteins that interact with MDM2 and p53, which provide an
important mechanism of regulating p53 protein stability and
expression [7].
The number of proteins implicated in regulation of p53
protein stability and degradation by modulating p53-MDM2
interaction is growing [8, 9]. By regulating this interaction,
these proteins function as p53 degradation-promoting or
-protecting molecules [10]. According to a categorized search
of the literature using the IPA software program (Ingenuity
Systems), 366 studies reported molecular regulators of p53
degradation, and 284 studies reportedmolecular regulators of
p53 stabilization.These proteins participate in a variety of cel-
lular processes, including transcriptional regulation, stress-
response signaling, cell-cycle regulation, and metabolic pro-
cess. Therefore, these proteins provide cells with diverse
regulatory mechanisms for control of p53 protein expression
in response to different cellular statuses. By positively or
negatively regulating p53 expression, these proteins may
suppress or promote tumor development, respectively.
Genetic and Chemical Regulators of p53 Protein Stabil-
ity and Degradation. (i) Regulation of p53 stabilization
(𝑛 = 284): MDM2, CDKN2A, TP53, NQO1, doxorubicin,
EP300, MDM4, actinomycin D, deferoxamine, 𝛾-radiation,
DNA, TADA3, ultraviolet (UV) radiation, ionizing radiation,
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OTUB1, camptothecin, ATM, CHEK2, NQO2, 2-aminopur-
ine, BAG6, BARD1, CP-31398, E1a, NUMB, SIN3A, disrup-
tion, myxothiazol, phosphotyrosine-binding domain, rosco-
vitine, zidovudine, HSPD1, RB1, RPL23, USP7, oxidative
stress, BANP, BRCA1, CAV1, CDKN2AIP, CDT, CP-257042,
H-7, HIF1A, Hsp90, ING1, KRAS, MIR199A, PML, RPL11,
RPL5, S100A4, TAF9, TP53BP2, TPP2, UVB radiation, WT1,
X-ray radiation, ZNF668, benzyloxycarbonyl-Leu-Leu-Leu
aldehyde, bisindolylmaleimide, bortezomib, cardiomyocytes,
fludarabine, hydrogen peroxide, hypoxia, pX, radiation,
reactive oxygen species, romidepsin, stress, 2-methoxyes-
tradiol, 26s proteasome, 5-fluorouracil, ATF3, ATP, ATR,
BAX, CCND1, CDB3, CDK2, CDK5, CRE-like element,
CSNK2A1, DHRS2, DMTF1, E2F1, E6, GADD45A, GNL3,
HSPA1A/HSPA1B, HTT, HUWE1, Hct 116 cells, Hsp27, IRF1,
KDM6B, MAPK14, MYB, MYC, Mdm2 protein-binding
domain, NAA30, ONCOGENE, PD98059, PHA-533533,
PIN1, PLK1, PLRG1, POLR1A, PRKDC, PTEN, RB1CC1,
RFWD2, RNA polymerase II, 𝑆-nitrosoglutathione, TERT,
TGFB1, TOPORS, UIMC1, UVC radiation, VRK1, YWHAG,
YY1, anoxia, caffeine, carboxy terminal domain, cisplatin,
clasto-lactacystin 𝛽-lactone, cobalt chloride, cyclophos-
phamide, dicumarol, etoposide, genotoxic stress, methylni-
tronitrosoguanidine, mir-122, mitomycin C, mitoxantrone,
morphine, nutlin-3, sulforafan, trichostatin A, ursodeoxy-
cholic acid, and vincristine.
(ii) Regulation of p53 degradation (𝑛 = 366): MDM2,
TP53, E6, ubiquitin, dicumarol, benzyloxycarbonyl-Leu-
Leu-Leu aldehyde, COPS5, NQO1, UBE3A, MDM4, 26s
proteasome, CDKN2A, CAT, E1b, zinc finger, C3HC4 type
(RING finger), 20s proteasome, DHRS2, EIF2AK2, RAD23A,
curcumin, PIM1, RAD23B, TOPORS, WR 1065, digoxin,
etoposide, leptomycin B, ouabain, protein, zinc finger
domain, ABL1, ATF3, Ala-Ala-Phe-chloromethylketone,
CTNNB1, EIF2AK3, GSK3B, HTT, HUWE1, Jnk, NOTCH1,
PSMD10, RB1CC1, RBBP6, RFWD2, TSG101, TXN, Ube3,
YY1, dexamethasone, dsRNA, geldanamycin, lactacystin,
monorden, stress, 6,4󸀠-dihydroxyflavone, AKT1, ARRB2,
ATP, AURKA, Akt, BANP, BCAS2, CAPN1, CSN, CUL2,
CUL4A, CUL5, CUL7, E1a, E4orf6, EGTA, EP300, FBXW8,
HDAC1, HIF1A, human adenovirus type 12, human
adenovirus type 5, IKBKB, IKBKG, KAT5, LA-12, LDL,
LY294002, large T antigen, Lmp1, MAGEC2/MAGEC3,
MAPK1, MAPK3, Mageb, 𝑁-carbobenzyloxy-leucine-leu-
cine-norvalinal, NAMPT, NCL, NF2, NQO2, P38 MAPK,
PIM2, PKA, PML, POLR1A, PSMC1, PYR-41, RBX1, RFFL,
RNF34, RPL11, SMAD1, SMURF1, STUB1, SYVN1, TCEB1,
TPT1, TRIM28, UBE2D1, UBE2E1, UBIQUITIN LIGASE,
UBQLN1, UBQLN2, Ubch5, ubiquilin, XPO1, Z-Leu-Leu-
Leu-B(OH)2, ZNF668, 𝛽-estradiol, bortezomib, calpeptin,
chrysin, cycloheximide, epoxomicin, esculetin, hypericin,
nitric oxide, okadaic acid, roscovitine, and warfarin.
As reported in the literature, investigators have con-
ventionally studied the regulatory effects of these hundreds
of proteins as isolated molecular events, assessing their
effects on p53-MDM2 interaction individually. However, the
human biosystem is highly dynamic and complex. How the
interconnected regulatory network formed by these p53-
regulating proteins affects the functions of individual proteins
Table 1: Candidate p53-regulatory proteins.
Protein
BRCA1 Breast cancer 1, early onset
HDAC1 Histone deacetylase 1
PLK1 Polo-like kinase 1
PML Promyelocytic leukemia
CDKN2A Cyclin-dependent kinase inhibitor 2A
SMAD1 SMAD family member 1
WT1 Wilms tumor 1
RB1 Retinoblastoma 1
YY1 YY1 transcription factor
is an intriguing question. The answer to this question is
not only important for us to understand how dysfunctional
p53-regulating network contributes to tumor initiation and
progression, but also important for us to identify potential
mechanisms to rewire this dysfunctional network in cancer.
To answer this question, we performed a network analysis
using the IPA software program to identify any potential
molecular networks that may be formed by known p53
protein regulators.
We selected nine candidate proteins among the hundreds
of p53 regulators as representative examples of p53 protein
stability-regulating network (Table 1).Their interactions with
p53 and MDM2 have been well established in a series of
studies [11–19].We chose these proteins to form the system for
our simplified mathematical model because they have well-
established functions in cancer biology and a broad impact
on regulation of both genetic and epigenetic processes.
For instance, BRCA1 deficiency predisposes women to the
development of breast and ovarian cancer [20]. Also, Rb1
is the key cell-cycle regulator, and deficiency of it promotes
tumorigenesis in several human cancers [21]. Furthermore,
like transcriptional regulators such as SMAD1, YY1, andWT1,
HDAC1 functions as an epigenetic regulator of histone mod-
ification induced by acetylation [14–16]. In addition to their
biological backgrounds, these nine proteins also correspond
to critical nodes in the network structure generated with all
proteins. Some of these nodes are cut-vertices (nodes in a
graph/network whose removal disconnects the graph) and
others are crucial to the connectedness (graphs/networks
loses strong connectivity after removing these nodes).
As we expected, these proteins involved in regulation
of p53 protein expression form a complex network with
interconnected regulatory linkages (Figure 1).This simplified
version of the network consists of only 9 representative
candidate proteins; the entire network of hundreds of p53
regulators is expected to be much more complex.
As described above, numerous proteins interact with p53
and/or MDM2. In order to develop a systematic study of
interactions among proteins in a massive network, determi-
nation of how several proteins in a network interact with p53
is the first logical step. For example, protein 𝐴 may interact
with p53, and protein 𝐵 may interact with MDM2. If both
𝐴 and 𝐵 are present, however, their interactions with p53-
MDM2 are far more complicated than a simple linear sum
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Figure 1: The network formed by p53-regulatory proteins.
of or difference in their individual interactions. For example,
the presence of 𝐴may enhance or inhibit the presence of 𝐵.
Although the importance of this study is evident, there
is a surprising lack of consideration of this question. One
simple way to describe a large graph (with many “nodes”
and “edges”) is to assume that it can be approximated by a
random-like structure [22]. As described herein, we tested a
random walk model that presents a network of proteins as
a directed graph with a restarting point and used stationary
distribution to predict the potential impact of each protein in
this network on p53-MDM2 interaction.
2. Background and Methodology
In this model, a directed graph is constructed with each
protein represented by a node and each protein-protein
interaction represented by a directed edge between the nodes
corresponding to the proteins. An additional initial node
(𝑆) and an additional transition node (𝑇) are added to the
graph, such that 𝑆 has directed edges to and from all existing
nodes and 𝑇 has directed edges from all existing nodes and
a directed edge to 𝑆. Note that 𝑆 and 𝑇 are the artificial
nodes that are independent of the rest of the network nor p53
and MDM2: 𝑆, with directed edges to and from all nodes,
represents the impact on the network from other proteins
and the receiver of the impact from the network (through
𝑇); 𝑇, with directed edges from all nodes and to 𝑆, represents
the pathway through which the impact from the network is
converted to other proteins. With this setup, the model can
be applied to any networks that we wish to consider.
A random walker starts from the initial node. At each
step, the walker moves along the directed edges to a neigh-
boring node with equal probabilities. That is, if a node 𝐴 has
directed edges to 𝐵, 𝐶, and 𝐷, the random walker, when at
𝐴, will move to each of 𝐵, 𝐶, and 𝐷 with probability 1/3.
At each node, the directed edge from it to the transition
node serves as the chance of exiting the random walk to
external proteins. Also, the directed edge from the initial
node serves as the chance of restarting this random walk,
representing the impact from external proteins outside of this
network. Clearly, the higher the probability of a node being
visited by the random walker is, the more interference the
corresponding protein contributes to the network.
With a total of 𝑛 nodes in the directed graph, 𝑝
𝑖
denotes
the probability of the random walker being at the 𝑖th node.
The vector𝑃
𝑡
= (𝑝
1
, 𝑝
2
, . . . , 𝑝
𝑛
) is then the “state” after 𝑡 steps.
The sequence of𝑃
𝑡
as 𝑡 goes to infinity (i.e., the randomwalker
keeps walking forever) forms a Markov chain. The states are
also called the transition probabilities.
Generally speaking, the necessary and sufficient condi-
tions for convergence of Markov chains are “irreducible” [23]
and “aperiodic” [24]. In simpler terms, equivalent condition
are as follows.
(I) The graph is “strongly connected,” that is, every node
has a directed path towards another.
(II) The greatest common divisor of all cycle lengths is 1.
We claim that both of these conditions are satisfied in our
constructed network. First, the initial node 𝑆 has a directed
edge (hence, a directed path) to and from every other nodes
in the graph. For any pair of nodes 𝐴 and 𝐵, 𝐴 → 𝑆 →
𝐵 → 𝑆 → 𝐴 provides the necessary directed paths from
𝐴 to 𝐵 and vice versa. Thus, the graph under consideration
is strongly connected. Second, for any node 𝐴, the directed
cycle𝐴 → 𝑇 → 𝑆 → 𝐴 is of length 3. Also, for any directed
edge 𝐴 → 𝐵, the directed cycle 𝐴 → 𝐵 → 𝑇 → 𝑆 → 𝐴
is of length 4. Therefore, the greatest common divisor of all
cycle lengths is 1.
When a Markov chain converges, it has a unique limit. In
our terms, the transition probability 𝑃
𝑡
converges to a unique
vector 𝑃 as 𝑡 approaches infinity. This limit 𝑃 is the unique
“stationary probability” or “stationary distribution.” Such a
convergence indicates that if the random walking process
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goes on forever, the probability of each node (protein) being
visited (i.e., influencing the network) is a fixed value.
Using𝑀 to denote the adjacency matrix of the directed
graph with edge weights corresponding to the probabilities
(known as the transition matrix of this random walk), the
stationary distribution can be directly determined by solving
𝑃𝑀 = 𝑃. In other words, an eigenvector of the matrix𝑀− 𝐼
transposed, in which 𝐼 is the identity matrix.
As described above, we take 𝑃 as the vector of the
impact of this network on p53 and/or MDM2 expression.
That is, let 𝑃 = (𝑝
1
, 𝑝
2
, . . . , 𝑝
𝑛
), in which the first entry
corresponds to the initial node and the last corresponds to
the transition node.We take𝑋 to be the normalized vector of
(𝑝
2
, 𝑝
3
, . . . , 𝑝
𝑛−1
); that is,
𝑋 =
(𝑝
2
, 𝑝
3
, . . . , 𝑝
𝑛−1
)
𝑁
, (1)
in which 𝑁 is the norm ∑𝑛−1
𝑖=2
𝑝
𝑖
of (𝑝
2
, 𝑝
3
, . . . , 𝑝
𝑛−1
). The
resulting vector 𝑋 = (𝑥
2
, 𝑥
3
, . . . , 𝑥
𝑛−1
) provides a measure
of how each node interacts with p53 and/or MDM2. Among
these nodes in the network corresponding to 𝑥
2
, 𝑥
3
, . . . , 𝑥
𝑛−1
,
individual interactions of some of them with p53 and/or
MDM2 are not necessarily present. Their corresponding 𝑥
values therefore denote the percentages of these interactions
contributed to the network.
Figure 2 is a simple network having three original
nodes—𝐴, 𝐵 and 𝐶—with one directed link from 𝐵 to 𝐶, and
the initial node 𝑆 and transition node 𝑇 together with the
corresponding edges.
The corresponding transition matrix is
𝑀 =
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
0
1
3
1
3
1
3
0
1
2
0 0 0
1
2
1
3
0 0
1
3
1
3
1
2
0 0 0
1
2
1 0 0 0 0
]
]
]
]
]
]
]
]
]
]
]
]
]
]
]
]
. (2)
Solving 𝑃 = 𝑃𝑀 yields the non-zero solution 𝑃 = (1, 1/3,
1/3, 4/9, 1/2). Following the above calculations, we have𝑋 =
(0.3, 0.3, 0.4), in which the first 0.3 corresponds to 𝐴, the
second to 𝐵, and 0.4 corresponds to 𝐶. Thus, 30% of the
individual interactions of each of 𝐴 and 𝐵 with p53 and/or
MDM2 are effective in this network, whereas 40% of that of
𝐶 is effective. Note that 𝐴 and 𝐵 had no direct or indirect
interaction in the original network (without 𝑆 and 𝑇). Thus,
the same percentage for them makes perfect sense.
3. Results
The proposed method was applied to the network shown in
Figure 1. With the addition of 𝑆 and 𝑇, the resulted network
consists of 11 nodes with a transitionmatrix of dimension 11×
11:
0 0.1429 0.2000 0.2500 0.1250 0.1111 0.2000 0.5000 0.1429 0.3333 1.0000
0.1111 0 0.2000 0 0.1250 0.1111 0 0 0.1429 0 0
0.1111 0.1429 0 0 0 0.1111 0 0 0 0 0
0.1111 0 0 0 0.1250 0.1111 0 0 0 0 0
0.1111 0.1429 0 0.2500 0 0.1111 0 0 0.1429 0.3333 0
0.1111 0.1429 0.2000 0.2500 0.1250 0 0.2000 0 0.1429 0 0
0.1111 0 0 0 0 0.1111 0 0 0.1429 0 0
0.1111 0 0 0 0.1250 0 0 0 0 0 0
0.1111 0.1429 0.2000 0 0.1250 0.1111 0.2000 0 0 0 0
0.1111 0.1429 0 0 0.1250 0.1111 0.2000 0 0.1429 0 0
0 0.1429 0.2000 0.2500 0.1250 0.1111 0.2000 0.5000 0.1429 0.3333 0
. (3)
Taking the eigenvector with respect to eigenvalue 1, we have
(.7078, .2041, .1376, .1439, .2842, .2677,
.1411, .1142, .2288, .2340, .3539)
(4)
as the stationary distribution. By taking away the first and last
entry (which correspond to the artificial nodes 𝑆 and 𝑇) and
normalization, we have
(.1163, .0784, .0820, .1619, .1525,
.0804, .0650, .1303, .1333)
(5)
corresponding to the percentage of impact that each of the
nine protein has on the entire network. The result yields
a percentage of 15.25% for histone deacetylase 1 (HDAC1).
Compared with the average value of 11.1% for any gene in the
network, it suggests the importance of HDAC1 in its role of
influencing p53-MDM2, not just as an individual gene, but
also as part of a networkwith other genes. Indeed,HDAC1has
an enzymatic function to remove acetylation modification
from proteins such as histone protein and p53 [25]. It also
interacts with many epigenetic regulators such as chromatin
remodeling factors, histone modification factors, and DNA
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methylation enzymes [26]. Thus it has a broad effect on
cell growth, arrest, differentiation, and death via regulating
epigenetic process [27]. These diverse biological functions of
HDAC1 may explain its importance as a key p53 regulator
implied through our mathematical analysis.
4. Discussion
The balance of p53 andMDM2 interaction with degradation-
promoting and -protecting proteins eventually dictates p53
stability [8]. As we describe herein, this balance is likely
affected by the complex array of protein interactions rather
than a single molecular event mediated by an individual
protein. Because of the complexity of the real biological
system of cells, it is virtually impossible to experimentally
dissecting and analyzing the common outcome of the protein
network involved in regulation of p53 expression.Therefore, a
mathematical model that can be used to analyze the common
biological effects of the protein network on regulation of p53
protein expression is urgently needed.
In the present study, we used the random walk procedure
with directed graphs to determine the comprehensive effects
of the protein regulatory network on p53-MDM2 interaction.
Simply put, the main advantage of this procedure lies in the
fact that the stationary distribution can be instantly solved
(hence, with minimum complexity) as an eigenvector of
the transition matrix generated by the given network. The
larger the corresponding value of a node in the stationary
distribution is, the more likely the corresponding protein’s
individual interaction with p53 and MDM2 takes effect as
part of the network.
p53 is an attractive therapeutic target for cancer because
its tumor-suppressive activity can be stimulated to eradicate
tumor cells [9]. Inhibiting physical p53-MDM2 interaction
is a promising approach to reactivating p53. Therefore, this
studymay provide a general paradigm that outlines the inter-
play among known proteins interacting with p53-MDM2 and
regulating p53 stability. Mathematically modeling the protein
interactions that control p53-MDM2 interactionmay provide
biological insight into how the balance of their interacting
proteins can be changed to ensure fine-tuned regulation of
p53 stability.
In addition, to prevent tumorigenesis, molecular mecha-
nisms similar to the p53 protein regulatory network can be
found in the cellular systems that regulate other key tumor
suppressors, such as PTEN. PTEN expression is lost in more
than 50% of tumors [28]. However, PTEN mutations are not
common in tumors [29]. Instead, dysfunctional regulation of
PTEN expression at the protein level is a common initiating
event in cancer development [29]. As mentioned earlier, the
use of nodes 𝑆 and 𝑇 enables one to examine networks with
any number of nodes.Therefore ourmathematical model can
be potentially used to examine additionalmolecular events in
tumor suppression [30].
5. Conclusion and Future Work
In our study, we applied mathematical methods and concepts
including random walk and stationary distribution to dissect
the complexity of protein network in cancer biology. Our
result shows that these methods can be used to identify key
nodes in the protein network, which may not be readily
determined by biological experiments studying individual
protein as an isolated molecular event. This approach pro-
vides an advantage to analyze the functions of a group of
genes or proteins as a network in cancer cells, which is not
only important for our understanding of cancer etiology, but
also for developing new therapeutic strategies.
p53 regulators identified by the IPA software pro-
gram (Ingenuity Systems) from existing biology studies are
involved in a variety ofmolecular pathways, that form diverse
functional groups such as gene expression, DNA repair
and replication, cell death and survival, cellular develop-
ment, carbohydrate metabolism, cell-to-cell signaling and
interaction, cell cycle, cell-mediated immune response, and
posttranslational modifications. To fully realize the potential
of the proposedmodel, we will (as a referee kindly suggested)
apply the discussed method to networks of reasonable size
formed by groups of proteins (according to the similarity of
their functions). After analyzing each of these networks and
choosing the proteins of highest scores (from each network
resp.), themethod can be applied again to the network formed
by the chosen proteins. We expect very meaningful results
through this approach when we take the time to complete the
massive inputting and calculation.
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